On October 25, 2024, Homburger advised Molecular Partners, a clinical-stage biotechnology company, in the announcement of the pricing of an underwritten public offering. The offering consisted of 3,642,988 American Depositary Shares (ADSs), representing new shares, priced at $5.49 per
Tags :Karin Mattle
Müller Martini and Hunkeler, both renowned companies with innovative solutions for post-print paper processing, announced the combination of the two businesses. Müller Martini Holding has acquired all shares in Hunkeler Holding from the
Homburger provided legal services to Atlas Agro Holding on its latest investment deal, with Macquarie Asset Management committing up to USD 325 million in the company and its affiliated project entities through the Macquarie GIG Energy
Siegfried and DiNAQOR entered into an agreement relating to the acquisition by Siegfried of a 95% stake in DiNAQOR DiNAMIQS, a Swiss-based biotechnology company focused on the development and manufacturing of viral vectors for cell and
Solenis has announced that it has entered into a definitive merger agreement under which Solenis will acquire Diversey in an all-cash transaction valued at an enterprise value of approximately USD 4.6 billion. Upon completion of the
Karin Mattle and Stefan Blunschi joined the Homburger partnership. After three years at the las firm working as associate, Matlle has became partner. Karin Mattle’s practice focuses on public and private M&A
OC Oerlikon Corporation, a global innovation powerhouse for surface engineering, polymer processing and additive manufacturing, has signed a definitive agreement to acquire the Mendrisio based Riri, a leading provider of coated metal accessories for the
Solenis has entered into a definitive agreement to acquire Kolb Distribution‘s paper process chemicals business, a unit of KLK Kolb Group. The deal includes a long-term supply agreement, in which the KLK Kolb Group
Ginkgo Bioworks, a horizontal platform for cell programming, entered into a definitive purchase agreement to acquire FGen, a Swiss company specializing in strain development and optimization. Ginkgo Bioworks believes that FGen’s technology will significantly
Allosteric modulation company Addex Therapeutics has entered into a definitive agreement with Armistice Capital, a healthcare-focused institutional investor, pursuant to which Addex agreed to sell 3,752,202 shares in the form of 625,367 American Depositary Shares («ADSs») at